ArticleJMIR bioinformatics and biotechnology2025
Protein-Protein Interactions in Papillary and Nonpapillary Urothelial Carcinoma Architectures: Comparative Study.
Article in JMIR bioinformatics and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer is a disease characterized by complex perturbations in gene networks and is heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology-based approaches have been used to identify complex protein-protein interactions (PPIs) that can lead to potential drug targets. There is a need to better understand PPIs specific to urothelial carcinoma. Objective: This study aimed to elucidate PPIs specific to papillary and nonpapillary urothelial carcinoma and identify the most connected or "hub" proteins, as these are potential drug targets. Methods: A novel PPI analysis tool, Proteinarium, was used to analyze RNA sequencing data from 132 patients with papillary and 270 patients with nonpapillary urothelial carcinoma from the TCGA Cell 2017 dataset and 39 patients with papillary and 88 patients with nonpapillary urothelial carcinoma from the TCGA Nature 2014 dataset. Hub proteins were identified in distinct PPI networks specific to papillary and nonpapillary urothelial carcinoma. Statistical significance of clusters was assessed using the Fisher exact test (P<.001), and network separation was quantified using the interactome-based separation score. Results: RPS27A, UBA52, and VAMP8 were the most connected or "hub" proteins identified in the network specific to the papillary urothelial carcinoma. In the network specific to the nonpapillary carcinoma, GNB1, RHOA, UBC, and FPR2 were found to be the hub proteins. Notably, GNB1 and FPR2 were among the proteins that have existing drugs targeting them. Conclusions: We identified distinct PPI networks and the hub proteins specific to papillary and nonpapillary urothelial carcinomas. However, these findings are limited by the use of transcriptomic data and require experimental validation to confirm the functional relevance of the identified targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.